Astrazeneca (AZN) Free Cash Flow Growth (3y) (2012 - 2026)
Astrazeneca (AZN) Free Cash Flow Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (3y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
41.47% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-15.10% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
-3.92% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
30.35% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
106.58% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
27.06% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
14.07% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
210.20% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
27.23% |
| 10 |
Biogen |
30.87 Bn |
26.59 Bn |
1.82 Bn |
15.20% |
| Date | Value |
|---|
| Mar 31, 2026 |
30.35% |
| Jun 30, 2025 |
37.59% |
| Mar 31, 2025 |
25.12% |
| Dec 31, 2024 |
-48.86% |
| Sep 30, 2024 |
17.05% |
| Mar 31, 2024 |
33.87% |
| Jun 30, 2023 |
26.72% |
| Mar 31, 2022 |
44.67% |
| Sep 30, 2021 |
-34.58% |
| Dec 31, 2019 |
-15.40% |
| Mar 31, 2019 |
-45.73% |
| Sep 30, 2018 |
47.62% |
| Dec 31, 2016 |
-62.81% |
| Mar 31, 2016 |
19.50% |
| Dec 31, 2015 |
-51.12% |
| Sep 30, 2015 |
20.99% |
| Jun 30, 2015 |
17.00% |
| Mar 31, 2015 |
0.91% |
| Dec 31, 2014 |
-16.02% |
| Sep 30, 2014 |
1.77% |
